CN113322299A - Drug target recognition method for depression and drug addiction diseases - Google Patents
Drug target recognition method for depression and drug addiction diseases Download PDFInfo
- Publication number
- CN113322299A CN113322299A CN202110590004.XA CN202110590004A CN113322299A CN 113322299 A CN113322299 A CN 113322299A CN 202110590004 A CN202110590004 A CN 202110590004A CN 113322299 A CN113322299 A CN 113322299A
- Authority
- CN
- China
- Prior art keywords
- drug
- depression
- lithium chloride
- steps
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003596 drug target Substances 0.000 title claims abstract description 48
- 238000000034 method Methods 0.000 title claims abstract description 45
- 206010013663 drug dependence Diseases 0.000 title claims abstract description 28
- 208000011117 substance-related disease Diseases 0.000 title claims abstract description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 21
- 239000003814 drug Substances 0.000 claims abstract description 133
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 claims abstract description 114
- 229940079593 drug Drugs 0.000 claims abstract description 79
- 239000000935 antidepressant agent Substances 0.000 claims abstract description 47
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 22
- 108090000790 Enzymes Proteins 0.000 claims abstract description 17
- 102000004190 Enzymes Human genes 0.000 claims abstract description 17
- 102000004310 Ion Channels Human genes 0.000 claims abstract description 17
- 230000000694 effects Effects 0.000 claims abstract description 17
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 16
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 16
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 16
- 229910003002 lithium salt Inorganic materials 0.000 claims abstract description 15
- 159000000002 lithium salts Chemical class 0.000 claims abstract description 15
- 108090000862 Ion Channels Proteins 0.000 claims abstract description 14
- 230000000857 drug effect Effects 0.000 claims abstract description 8
- 230000004927 fusion Effects 0.000 claims abstract description 8
- 230000003204 osmotic effect Effects 0.000 claims abstract description 8
- 241000699800 Cricetinae Species 0.000 claims description 31
- 230000009471 action Effects 0.000 claims description 29
- 238000004458 analytical method Methods 0.000 claims description 22
- 238000000926 separation method Methods 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 15
- 206010012335 Dependence Diseases 0.000 claims description 14
- 238000001514 detection method Methods 0.000 claims description 14
- 238000004043 dyeing Methods 0.000 claims description 14
- 238000002347 injection Methods 0.000 claims description 14
- 239000007924 injection Substances 0.000 claims description 14
- 239000008280 blood Substances 0.000 claims description 13
- 210000004369 blood Anatomy 0.000 claims description 13
- 239000011550 stock solution Substances 0.000 claims description 13
- 230000008595 infiltration Effects 0.000 claims description 12
- 238000001764 infiltration Methods 0.000 claims description 12
- 239000003153 chemical reaction reagent Substances 0.000 claims description 10
- 230000001430 anti-depressive effect Effects 0.000 claims description 9
- 229940005513 antidepressants Drugs 0.000 claims description 9
- 238000012360 testing method Methods 0.000 claims description 9
- YVPYQUNUQOZFHG-UHFFFAOYSA-N amidotrizoic acid Chemical compound CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I YVPYQUNUQOZFHG-UHFFFAOYSA-N 0.000 claims description 8
- 229960005423 diatrizoate Drugs 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 230000008859 change Effects 0.000 claims description 7
- 239000012154 double-distilled water Substances 0.000 claims description 7
- 238000003255 drug test Methods 0.000 claims description 7
- 238000000605 extraction Methods 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- 229960005133 diatrizoate meglumine Drugs 0.000 claims description 6
- 238000001727 in vivo Methods 0.000 claims description 6
- MIKKOBKEXMRYFQ-WZTVWXICSA-N meglumine amidotrizoate Chemical compound C[NH2+]C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I MIKKOBKEXMRYFQ-WZTVWXICSA-N 0.000 claims description 6
- 230000036651 mood Effects 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 229960005017 olanzapine Drugs 0.000 claims description 5
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims description 5
- 229960004431 quetiapine Drugs 0.000 claims description 5
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 claims description 5
- 229960000607 ziprasidone Drugs 0.000 claims description 5
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 claims description 5
- 230000003187 abdominal effect Effects 0.000 claims description 3
- 239000011324 bead Substances 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 210000000056 organ Anatomy 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 239000000284 extract Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241001539473 Euphoria Species 0.000 description 1
- 206010015535 Euphoric mood Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000007084 physiological dysfunction Effects 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
Abstract
The invention discloses a method for identifying drug targets of depression and drug addiction diseases, which comprises the following steps of taking a plurality of samples of drug groups to be detected, taking a plurality of groups of effective cell samples to be respectively dyed, carrying out full fusion of different drug groups to be detected and a plurality of groups of effective cells for 30min respectively after the effective cells in cells comprise enzymes, ion channels, gene loci, receptors and nucleic acids, respectively adding lithium chloride with different concentrations, detecting the drug osmotic concentration curve every 30min, an experimental group which can analyze the cell activity under the state of lithium salt with different concentrations, can achieve the longest drug effect and keep the cell activity in a stable state, the invention separates and extracts the detected position of the drug target point A again to obtain the drug target point in a pollution-free state, and searches for a new antidepressant drug A according to the specific components of the drug target point.
Description
Technical Field
The invention belongs to the technical field of drug target recognition, and particularly relates to a drug target recognition method for depression and drug addiction diseases.
Background
The addictive drugs refer to some prescription drugs which are commonly used clinically for anesthesia, analgesia, antianxiety and antidepressant; the medicines are reasonably used under the guidance of doctors and have good curative effect, if the medicines are excessively used, people can feel euphoria, serious physical dependence and psychological dependence can be generated after continuous use, physiological dysfunction can be caused after medicine withdrawal, withdrawal symptoms can appear, the combining part of the medicines and organism biomacromolecules is a medicine target spot, the medicine action target spot relates to receptors, enzymes, ion channels, transporters, immune systems, genes and the like, in addition, some medicines play a role through the physicochemical action or supplement substances lacking in the organism, in the existing medicines, more than 50 percent of the medicines take the receptors as the action target spots, and the receptors become the most main and important action target spots; more than 20% of the drugs take enzyme as an action target, particularly enzyme inhibitors, and have special positions in clinical application; about 6% of the drugs take ion channels as action targets; 3% of the medicine takes nucleic acid as an action target; the action targets of 20% of the drugs are still to be further researched.
The identification process of the drug target is often accompanied with the identification of the drug mixture, and the target has the mixture of other drugs, so that the accuracy of the experimental result is not enough.
Disclosure of Invention
The invention aims to overcome the defects in the prior art and provide a method for identifying drug targets of depression and drug addiction diseases so as to solve the problem of insufficient accuracy of experimental results in the background technology.
In order to achieve the purpose, the invention provides the following technical scheme: a method for identifying drug targets of depression and drug addiction diseases comprises the following steps:
the method comprises the following steps: collecting samples, taking a plurality of samples of drug groups to be tested, taking a plurality of groups of effective cell samples for respective dyeing, wherein the cells comprise enzymes, ion channels, gene loci, receptors and nucleic acids, fully fusing different drug groups to be tested with a plurality of groups of effective cells for 30min, respectively adding lithium chloride with different concentrations, detecting a drug osmotic concentration curve every 30min, and analyzing cell activity under the state that lithium salts with different concentrations are fused, so that an experimental group which can achieve the longest drug effect and keep the cell activity in a stable state is the optimal lithium chloride concentration for addiction treatment;
step two: and (3) component analysis: for the identification of the drug action target, analyzing the reagent with the optimal lithium chloride concentration in the step one, detecting the drug binding site at the position of the lithium salt, searching binding sites except for enzyme, ion channel, gene site, receptor and nucleic acid, analyzing whether the drug target A is the key action target, and extracting the components of the binding site for analysis;
step three: component separation: respectively carrying out high-temperature and electrolytic separation on the combined target spots of the medicaments, adding a proper amount of double distilled water into a stock solution of diatrizoate meglumine, mixing the mixture into 20% of low-concentration diatrizoate, adding the mixture into a sample to be tested to layer the stock solution, extracting a medicament target spot A in the sample to carry out single medicament mixing detection, taking an effective cell sample, carrying out independent dyeing extraction on the medicament target spot A extracted from effective cells to carry out component analysis, obtaining a medicament target spot in a medicament pollution-free state, and searching for a new antidepressant medicament A according to specific components of the medicament target spot;
step four: in vivo test: taking a plurality of adult hamsters to carry out a separate drug test, injecting an antidepressant drug solvent into the hamsters once every 24h, continuously injecting for 15 times, then converting into injecting the antidepressant drug once every 48h, simultaneously using the lithium chloride with the optimal concentration obtained in the step one to inject, carrying out blood drawing detection once every 48h, and judging the mood and the heart fluctuation state of the adult hamsters under the action of the lithium chloride;
step five: the addiction relieving process comprises the following steps: if the heart rate does not change obviously before and after injection, the antidepressant drug A and the lithium chloride with the optimal concentration are sequentially converted every 72 hours, and the antidepressant drug A and the lithium chloride with the optimal concentration are continuously injected every 96 hours after three times until the drug addiction state disappears.
Preferably, in the first step, the sample of the drug group to be tested is an existing drug for depression, such as olanzapine, ziprasidone, quetiapine and the like.
Preferably, in the first step, the drug group to be tested is directly dropped into a culture dish of effective cells for infiltration fusion, and the drug infiltration concentration detected every 30min is recorded to prepare a drug infiltration concentration curve.
Preferably, the drug target point A in the second step is the identified novel drug target point.
Preferably, the reagent concentration of lithium chloride in the second step is 1%, 10%, 20%, 30%, 40% and 50% in sequence.
Preferably, in the third step, an immunomagnetic bead separation method is adopted to separate the cells, and the control protein sample is obtained after the protein is cracked and centrifuged by heat treatment at high temperature for 5min, and the cracked cells are further layered.
Preferably, antidepressant drug A in step three may be a fusion of a plurality of antidepressant drug components.
Preferably, the adult hamsters in step four are all hamsters with normal function of each organ, and abdominal injection is selected when the drug is injected.
Preferably, the blood is drawn from the test hamster in the fourth step by intravenous blood drawing.
Preferably, the dose of the antidepressant drug and the lithium chloride in the single injection in the fifth step are the same.
Compared with the prior art, the invention provides a method for identifying the drug target of depression and drug addiction diseases, which has the following beneficial effects:
1. the invention obtains the drug target point in an impurity-free state by re-separating and extracting the position of the detected drug target point A, and searches for a new antidepressant drug A according to the specific components of the drug target point.
2. The invention can slowly release the addiction of the medicine by the arranged lithium chloride to avoid the dependence of a patient on the medicine, and experiments are carried out by a plurality of groups of effective cell samples and hamster living bodies.
Drawings
The accompanying drawings, which are included to provide a further understanding of the invention and are incorporated in and constitute a part of this specification, illustrate embodiments of the invention and together with the description serve to explain the principles of the invention without limiting the invention in which:
FIG. 1 is a schematic diagram of the identification steps and target point testing structure provided by the present invention.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example one
A method for identifying drug targets of depression and drug addiction diseases comprises the following steps:
the method comprises the following steps: collecting samples, taking a plurality of samples of drug groups to be tested, taking a plurality of groups of effective cell samples for respective dyeing, wherein the cells comprise enzymes, ion channels, gene loci, receptors and nucleic acids, fully fusing different drug groups to be tested with a plurality of groups of effective cells for 30min, respectively adding lithium chloride with different concentrations, detecting a drug osmotic concentration curve every 30min, and analyzing cell activity under the state that lithium salts with different concentrations are fused, so that an experimental group which can achieve the longest drug effect and keep the cell activity in a stable state is the optimal lithium chloride concentration for addiction treatment;
step two: and (3) component analysis: for the identification of the drug action target, analyzing the reagent with the optimal lithium chloride concentration in the step one, detecting the drug binding site at the position of the lithium salt, searching binding sites except for enzyme, ion channel, gene site, receptor and nucleic acid, analyzing whether the drug target A is the key action target, and extracting the components of the binding site for analysis;
step three: component separation: respectively carrying out high-temperature and electrolytic separation on the combined target spots of the medicaments, adding a proper amount of double distilled water into a stock solution of diatrizoate meglumine, mixing the mixture into 20% of low-concentration diatrizoate, adding the mixture into a sample to be tested to layer the stock solution, extracting a medicament target spot A in the sample to carry out single medicament mixing detection, taking an effective cell sample, carrying out independent dyeing extraction on the medicament target spot A extracted from effective cells to carry out component analysis, obtaining a medicament target spot in a medicament pollution-free state, and searching for a new antidepressant medicament A according to specific components of the medicament target spot;
step four: in vivo test: taking a plurality of adult hamsters to carry out a separate drug test, injecting an antidepressant drug solvent into the hamsters once every 24h, continuously injecting for 15 times, then converting into injecting the antidepressant drug once every 48h, simultaneously using the lithium chloride with the optimal concentration obtained in the step one to inject, carrying out blood drawing detection once every 48h, and judging the mood and the heart fluctuation state of the adult hamsters under the action of the lithium chloride;
step five: the addiction relieving process comprises the following steps: if the heart rate does not change obviously before and after injection, the antidepressant drug A and the lithium chloride with the optimal concentration are sequentially converted every 72 hours, and the antidepressant drug A and the lithium chloride with the optimal concentration are continuously injected every 96 hours after three times until the drug addiction state disappears.
Example two
A method for identifying drug targets of depression and drug addiction diseases comprises the following steps:
the method comprises the following steps: collecting samples, taking a plurality of samples of drug groups to be tested, taking a plurality of groups of effective cell samples for respective dyeing, wherein the cells comprise enzymes, ion channels, gene loci, receptors and nucleic acids, fully fusing different drug groups to be tested with a plurality of groups of effective cells for 30min, respectively adding lithium chloride with different concentrations, detecting a drug osmotic concentration curve every 30min, and analyzing cell activity under the state that lithium salts with different concentrations are fused, so that an experimental group which can achieve the longest drug effect and keep the cell activity in a stable state is the optimal lithium chloride concentration for addiction treatment;
step two: and (3) component analysis: for the identification of the drug action target, analyzing the reagent with the optimal lithium chloride concentration in the step one, detecting the drug binding site at the position of the lithium salt, searching binding sites except for enzyme, ion channel, gene site, receptor and nucleic acid, analyzing whether the drug target A is the key action target, and extracting the components of the binding site for analysis;
step three: component separation: respectively carrying out high-temperature and electrolytic separation on the combined target spots of the medicaments, adding a proper amount of double distilled water into a stock solution of diatrizoate meglumine, mixing the mixture into 20% of low-concentration diatrizoate, adding the mixture into a sample to be tested to layer the stock solution, extracting a medicament target spot A in the sample to carry out single medicament mixing detection, taking an effective cell sample, carrying out independent dyeing extraction on the medicament target spot A extracted from effective cells to carry out component analysis, obtaining a medicament target spot in a medicament pollution-free state, and searching for a new antidepressant medicament A according to specific components of the medicament target spot;
step four: in vivo test: taking a plurality of adult hamsters to carry out a separate drug test, injecting an antidepressant drug solvent into the hamsters once every 24h, continuously injecting for 15 times, then converting into injecting the antidepressant drug once every 48h, simultaneously using the lithium chloride with the optimal concentration obtained in the step one to inject, carrying out blood drawing detection once every 48h, and judging the mood and the heart fluctuation state of the adult hamsters under the action of the lithium chloride;
step five: the addiction relieving process comprises the following steps: if the heart rate does not change obviously before and after injection, the antidepressant drug A and the lithium chloride with the optimal concentration are sequentially converted every 72 hours, and the antidepressant drug A and the lithium chloride with the optimal concentration are continuously injected every 96 hours after three times until the drug addiction state disappears.
In the present invention, preferably, in the step one, the sample of the drug group to be tested is an existing drug for depression, such as olanzapine, ziprasidone, quetiapine, and the like.
EXAMPLE III
A method for identifying drug targets of depression and drug addiction diseases comprises the following steps:
the method comprises the following steps: collecting samples, taking a plurality of samples of drug groups to be tested, taking a plurality of groups of effective cell samples for respective dyeing, wherein the cells comprise enzymes, ion channels, gene loci, receptors and nucleic acids, fully fusing different drug groups to be tested with a plurality of groups of effective cells for 30min, respectively adding lithium chloride with different concentrations, detecting a drug osmotic concentration curve every 30min, and analyzing cell activity under the state that lithium salts with different concentrations are fused, so that an experimental group which can achieve the longest drug effect and keep the cell activity in a stable state is the optimal lithium chloride concentration for addiction treatment;
step two: and (3) component analysis: for the identification of the drug action target, analyzing the reagent with the optimal lithium chloride concentration in the step one, detecting the drug binding site at the position of the lithium salt, searching binding sites except for enzyme, ion channel, gene site, receptor and nucleic acid, analyzing whether the drug target A is the key action target, and extracting the components of the binding site for analysis;
step three: component separation: respectively carrying out high-temperature and electrolytic separation on the combined target spots of the medicaments, adding a proper amount of double distilled water into a stock solution of diatrizoate meglumine, mixing the mixture into 20% of low-concentration diatrizoate, adding the mixture into a sample to be tested to layer the stock solution, extracting a medicament target spot A in the sample to carry out single medicament mixing detection, taking an effective cell sample, carrying out independent dyeing extraction on the medicament target spot A extracted from effective cells to carry out component analysis, obtaining a medicament target spot in a medicament pollution-free state, and searching for a new antidepressant medicament A according to specific components of the medicament target spot;
step four: in vivo test: taking a plurality of adult hamsters to carry out a separate drug test, injecting an antidepressant drug solvent into the hamsters once every 24h, continuously injecting for 15 times, then converting into injecting the antidepressant drug once every 48h, simultaneously using the lithium chloride with the optimal concentration obtained in the step one to inject, carrying out blood drawing detection once every 48h, and judging the mood and the heart fluctuation state of the adult hamsters under the action of the lithium chloride;
step five: the addiction relieving process comprises the following steps: if the heart rate does not change obviously before and after injection, the antidepressant drug A and the lithium chloride with the optimal concentration are sequentially converted every 72 hours, and the antidepressant drug A and the lithium chloride with the optimal concentration are continuously injected every 96 hours after three times until the drug addiction state disappears.
In the present invention, preferably, in the step one, the sample of the drug group to be tested is an existing drug for depression, such as olanzapine, ziprasidone, quetiapine, and the like.
In the present invention, preferably, in the first step, the drug group to be tested is directly dropped into a culture dish of effective cells for infiltration fusion, and the drug infiltration concentration detected every 30min is recorded to prepare a drug infiltration concentration curve.
In the present invention, preferably, the drug target point a in step two is the identified novel drug target point.
Example four
A method for identifying drug targets of depression and drug addiction diseases comprises the following steps:
the method comprises the following steps: collecting samples, taking a plurality of samples of drug groups to be tested, taking a plurality of groups of effective cell samples for respective dyeing, wherein the cells comprise enzymes, ion channels, gene loci, receptors and nucleic acids, fully fusing different drug groups to be tested with a plurality of groups of effective cells for 30min, respectively adding lithium chloride with different concentrations, detecting a drug osmotic concentration curve every 30min, and analyzing cell activity under the state that lithium salts with different concentrations are fused, so that an experimental group which can achieve the longest drug effect and keep the cell activity in a stable state is the optimal lithium chloride concentration for addiction treatment;
step two: and (3) component analysis: for the identification of the drug action target, analyzing the reagent with the optimal lithium chloride concentration in the step one, detecting the drug binding site at the position of the lithium salt, searching binding sites except for enzyme, ion channel, gene site, receptor and nucleic acid, analyzing whether the drug target A is the key action target, and extracting the components of the binding site for analysis;
step three: component separation: respectively carrying out high-temperature and electrolytic separation on the combined target spots of the medicaments, adding a proper amount of double distilled water into a stock solution of diatrizoate meglumine, mixing the mixture into 20% of low-concentration diatrizoate, adding the mixture into a sample to be tested to layer the stock solution, extracting a medicament target spot A in the sample to carry out single medicament mixing detection, taking an effective cell sample, carrying out independent dyeing extraction on the medicament target spot A extracted from effective cells to carry out component analysis, obtaining a medicament target spot in a medicament pollution-free state, and searching for a new antidepressant medicament A according to specific components of the medicament target spot;
step four: in vivo test: taking a plurality of adult hamsters to carry out a separate drug test, injecting an antidepressant drug solvent into the hamsters once every 24h, continuously injecting for 15 times, then converting into injecting the antidepressant drug once every 48h, simultaneously using the lithium chloride with the optimal concentration obtained in the step one to inject, carrying out blood drawing detection once every 48h, and judging the mood and the heart fluctuation state of the adult hamsters under the action of the lithium chloride;
step five: the addiction relieving process comprises the following steps: if the heart rate does not change obviously before and after injection, the antidepressant drug A and the lithium chloride with the optimal concentration are sequentially converted every 72 hours, and the antidepressant drug A and the lithium chloride with the optimal concentration are continuously injected every 96 hours after three times until the drug addiction state disappears.
In the present invention, preferably, in the step one, the sample of the drug group to be tested is an existing drug for depression, such as olanzapine, ziprasidone, quetiapine, and the like.
In the present invention, preferably, in the first step, the drug group to be tested is directly dropped into a culture dish of effective cells for infiltration fusion, and the drug infiltration concentration detected every 30min is recorded to prepare a drug infiltration concentration curve.
In the present invention, preferably, the drug target point a in step two is the identified novel drug target point.
In the present invention, it is preferable that the reagent concentration of lithium chloride in the second step is 1%, 10%, 20%, 30%, 40% and 50% in this order.
In the present invention, preferably, in the third step, the immunomagnetic bead separation method is adopted to separate the cells, the high temperature heat treatment is performed for 5min to lyse and centrifuge the protein to obtain a control protein sample, and the lysed cells are further layered.
In the present invention, preferably, antidepressant a in step three may be a fusion of a plurality of antidepressant pharmaceutical ingredients.
In the present invention, it is preferable that all adult hamsters in step four are hamsters with normal function of each organ, and abdominal injection is selected when the drug is injected.
In the present invention, the mode of drawing blood from the test hamster in step four is preferably venous blood drawing.
In the present invention, preferably, the dosage of the antidepressant drug and the lithium chloride in the fifth step is the same.
The working principle and the using process of the invention are as follows: when in use, a plurality of drug group samples to be tested are taken, a plurality of groups of effective cell samples are taken for respective dyeing, the cells comprise enzyme, ion channels, gene sites, receptors and nucleic acid, different drug groups to be tested are respectively and fully fused with a plurality of groups of effective cells for 30min, lithium chloride with different concentrations is respectively added, a drug osmotic concentration curve is detected every 30min, cell activity analysis is carried out under the state that lithium salts with different concentrations are fused, an experimental group which can achieve the longest drug effect and keep the cell activity in a stable state is the optimal lithium chloride concentration for addiction treatment, the identification of drug action targets is carried out, a reagent with the optimal lithium chloride concentration in the first analysis step is used for detecting the drug binding points at the positions of the lithium salts, binding points except the enzyme, the ion channels, the gene sites, the receptors and the nucleic acid are searched, and whether the drug target A is a key action target is analyzed, extracting the components of the binding sites for analysis, respectively carrying out high-temperature and electrolytic separation on the targets after drug binding, taking diatrizoate stock solution, adding a proper amount of double distilled water, mixing to obtain 20% low-concentration diatrizoate, mixing, adding the mixture into a sample to be tested to layer the stock cell solution, extracting the drug target A in the sample to carry out single-item drug mixing detection, taking an effective cell sample, carrying out independent dyeing extraction on the drug target A extracted from the effective cells to carry out component analysis, obtaining the drug target under a drug pollution-free state, searching for a new antidepressant drug A according to the specific components of the drug target, taking a plurality of adult hamsters to carry out independent drug tests, injecting antidepressant drug solvent once every 24h into hamsters, continuously injecting for 15 times, converting into antidepressant drug injection once every 48 hours, and simultaneously injecting the lithium chloride with the optimal concentration obtained in the step one at the same time of injecting the drug every 48h, and blood drawing detection is carried out once at intervals of 48h, the emotion and heart fluctuation state of adult hamsters under the action of lithium chloride is judged, if the heart rate before and after injection has no obvious change, antidepressant drug A and lithium chloride with the optimal concentration are sequentially converted once every 72h, and antidepressant drug A and lithium chloride with the optimal concentration are continuously injected once every 96h after three times until the drug addiction state disappears.
Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that changes, modifications, substitutions and alterations can be made in these embodiments without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.
Claims (10)
1. A method for identifying drug targets of depression and drug addiction diseases is characterized in that: the method comprises the following steps:
the method comprises the following steps: collecting samples, taking a plurality of samples of drug groups to be tested, taking a plurality of groups of effective cell samples for respective dyeing, wherein the cells comprise enzymes, ion channels, gene loci, receptors and nucleic acids, fully fusing different drug groups to be tested with a plurality of groups of effective cells for 30min, respectively adding lithium chloride with different concentrations, detecting a drug osmotic concentration curve every 30min, and analyzing cell activity under the state that lithium salts with different concentrations are fused, so that an experimental group which can achieve the longest drug effect and keep the cell activity in a stable state is the optimal lithium chloride concentration for addiction treatment;
step two: and (3) component analysis: for the identification of the drug action target, analyzing the reagent with the optimal lithium chloride concentration in the step one, detecting the drug binding site at the position of the lithium salt, searching binding sites except for enzyme, ion channel, gene site, receptor and nucleic acid, analyzing whether the drug target A is the key action target, and extracting the components of the binding site for analysis;
step three: component separation: respectively carrying out high-temperature and electrolytic separation on the combined target spots of the medicaments, adding a proper amount of double distilled water into a stock solution of diatrizoate meglumine, mixing the mixture into 20% of low-concentration diatrizoate, adding the mixture into a sample to be tested to layer the stock solution, extracting a medicament target spot A in the sample to carry out single medicament mixing detection, taking an effective cell sample, carrying out independent dyeing extraction on the medicament target spot A extracted from effective cells to carry out component analysis, obtaining a medicament target spot in a medicament pollution-free state, and searching for a new antidepressant medicament A according to specific components of the medicament target spot;
step four: in vivo test: taking a plurality of adult hamsters to carry out a separate drug test, injecting an antidepressant drug solvent into the hamsters once every 24h, continuously injecting for 15 times, then converting into injecting the antidepressant drug once every 48h, simultaneously using the lithium chloride with the optimal concentration obtained in the step one to inject, carrying out blood drawing detection once every 48h, and judging the mood and the heart fluctuation state of the adult hamsters under the action of the lithium chloride;
step five: the addiction relieving process comprises the following steps: if the heart rate does not change obviously before and after injection, the antidepressant drug A and the lithium chloride with the optimal concentration are sequentially converted every 72 hours, and the antidepressant drug A and the lithium chloride with the optimal concentration are continuously injected every 96 hours after three times until the drug addiction state disappears.
2. The method of claim 1 for identifying drug targets in depression and drug addiction diseases, wherein the method comprises the following steps: in the first step, the sample of the drug group to be tested is the existing drugs aiming at depression, such as olanzapine, ziprasidone, quetiapine and the like.
3. The method of claim 1 for identifying drug targets in depression and drug addiction diseases, wherein the method comprises the following steps: in the first step, the drug group to be detected is directly dripped into a culture dish of effective cells for infiltration fusion, and the drug infiltration concentration detected every 30min is recorded to prepare a drug infiltration concentration curve.
4. The method of claim 1 for identifying drug targets in depression and drug addiction diseases, wherein the method comprises the following steps: and the drug target point A in the second step is the identified novel drug target point.
5. The method of claim 1 for identifying drug targets in depression and drug addiction diseases, wherein the method comprises the following steps: and in the second step, the concentration of the lithium chloride reagent is 1%, 10%, 20%, 30%, 40% and 50% in sequence.
6. The method of claim 1 for identifying drug targets in depression and drug addiction diseases, wherein the method comprises the following steps: and in the third step, an immunomagnetic bead separation method is adopted for cell separation, high-temperature heat treatment is carried out for 5min to crack and centrifuge the protein to obtain a control protein sample, and the cracked cells are further layered.
7. The method of claim 1 for identifying drug targets in depression and drug addiction diseases, wherein the method comprises the following steps: the antidepressant drug A in the third step can be a fusion of a plurality of antidepressant drug components.
8. The method of claim 1 for identifying drug targets in depression and drug addiction diseases, wherein the method comprises the following steps: the adult hamsters in step four were all hamsters with normal function of each organ, and abdominal injection was selected for the injection of the drug.
9. The method of claim 1 for identifying drug targets in depression and drug addiction diseases, wherein the method comprises the following steps: the blood was drawn from the experimental hamster in step four by intravenous blood draw.
10. The method of claim 1 for identifying drug targets in depression and drug addiction diseases, wherein the method comprises the following steps: the doses of the antidepressant drug and the lithium chloride in the single injection in the step five are the same.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110590004.XA CN113322299A (en) | 2021-05-28 | 2021-05-28 | Drug target recognition method for depression and drug addiction diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110590004.XA CN113322299A (en) | 2021-05-28 | 2021-05-28 | Drug target recognition method for depression and drug addiction diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113322299A true CN113322299A (en) | 2021-08-31 |
Family
ID=77422021
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110590004.XA Pending CN113322299A (en) | 2021-05-28 | 2021-05-28 | Drug target recognition method for depression and drug addiction diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113322299A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113337570A (en) * | 2021-05-28 | 2021-09-03 | 南昌大学 | Mechanism analysis system for drug target of depression and drug addiction disease |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060150989A1 (en) * | 2005-01-12 | 2006-07-13 | Peter Migaly | Method of diagnosing, treating and educating individuals with and/or about depression |
| JP2007330220A (en) * | 2006-06-19 | 2007-12-27 | Osaka Bioscience Institute | Screening system for antidepressant and screening method using the same |
| CN101491538A (en) * | 2008-12-30 | 2009-07-29 | 北京大学 | Use of lithium salt in preparing medicine for treating addict to psychostimulant |
| WO2012137971A1 (en) * | 2011-04-05 | 2012-10-11 | Otsuka Pharmaceutical Co., Ltd. | Combinations comprising brexpiprazole or a salt thereof and a second drug for use in the treatment of a cns disorder |
| CN105920034A (en) * | 2016-05-30 | 2016-09-07 | 宁波大学 | Application of lithium chloride to preparation of methamphetamine cognitive disorder medicament |
| US20180296554A1 (en) * | 2015-06-30 | 2018-10-18 | University Of South Florida | Inhibitors of the fkbp51 protein from a high-throughput drug screen and methods of use |
| US20210046049A1 (en) * | 2018-02-28 | 2021-02-18 | Instituto Nacional De Psiquiatría "Ramón De La Fuente Muñiz" | Pharmaceutical combination for mood disorders |
| CN113337570A (en) * | 2021-05-28 | 2021-09-03 | 南昌大学 | Mechanism analysis system for drug target of depression and drug addiction disease |
-
2021
- 2021-05-28 CN CN202110590004.XA patent/CN113322299A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060150989A1 (en) * | 2005-01-12 | 2006-07-13 | Peter Migaly | Method of diagnosing, treating and educating individuals with and/or about depression |
| JP2007330220A (en) * | 2006-06-19 | 2007-12-27 | Osaka Bioscience Institute | Screening system for antidepressant and screening method using the same |
| CN101491538A (en) * | 2008-12-30 | 2009-07-29 | 北京大学 | Use of lithium salt in preparing medicine for treating addict to psychostimulant |
| WO2012137971A1 (en) * | 2011-04-05 | 2012-10-11 | Otsuka Pharmaceutical Co., Ltd. | Combinations comprising brexpiprazole or a salt thereof and a second drug for use in the treatment of a cns disorder |
| US20180296554A1 (en) * | 2015-06-30 | 2018-10-18 | University Of South Florida | Inhibitors of the fkbp51 protein from a high-throughput drug screen and methods of use |
| CN105920034A (en) * | 2016-05-30 | 2016-09-07 | 宁波大学 | Application of lithium chloride to preparation of methamphetamine cognitive disorder medicament |
| US20210046049A1 (en) * | 2018-02-28 | 2021-02-18 | Instituto Nacional De Psiquiatría "Ramón De La Fuente Muñiz" | Pharmaceutical combination for mood disorders |
| CN113337570A (en) * | 2021-05-28 | 2021-09-03 | 南昌大学 | Mechanism analysis system for drug target of depression and drug addiction disease |
Non-Patent Citations (3)
| Title |
|---|
| BRYNNA S.EISELE等: ""Bisphosphate nucleotidase 2 (BPNT2), a molecular target of lithium, regulates chondroitin sulfation patterns in the cerebral cortex and hippocampus"", 《ADVANCES IN BIOLOGICAL REGULATION》 * |
| KELTY MENTAL HEALTH: ""在儿童和青少年中使用锂盐"", 《BC MENTAL HEALTH & ADDICTION SERVICES》 * |
| 梁建辉等: ""精神活性物质成瘾的行为医学研究"", 《中国药物依赖性杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113337570A (en) * | 2021-05-28 | 2021-09-03 | 南昌大学 | Mechanism analysis system for drug target of depression and drug addiction disease |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| King et al. | Endothelin: a potent renal and systemic vasoconstrictor peptide | |
| Ekblom et al. | Pharmacokinetics and pharmacodynamics of morphine‐3‐glucuronide in rats and its influence on the antinociceptive effect of morphine | |
| Valenzuela et al. | Effect of dopamine on human gastric and pancreatic secretion | |
| Takamatsu et al. | Treadmill running improves motor function and alters dendritic morphology in the striatum after collagenase-induced intracerebral hemorrhage in rats | |
| CN105349642B (en) | A kind of acute myocardial infarction AMI marker and its application | |
| CN109477144A (en) | Method for detecting hepatic fibrosis-renal tubular ectasia syndrome and the responsiveness to therapy | |
| CN113322299A (en) | Drug target recognition method for depression and drug addiction diseases | |
| CN114038574A (en) | Drug relocation system and method based on heterogeneous association network deep learning | |
| Cerletti et al. | Chronic morphine administration: plasma levels and withdrawal syndrome in rats | |
| Marinelli et al. | Pharmacological stimuli decreasing nucleus accumbens dopamine can act as positive reinforcers but have a low addictive potential | |
| Ni et al. | Therapeutic effect of berberine on 60 patients with non-insulin dependent diabetes mellitus and experimental research | |
| CN102415993B (en) | Pharmaceutical composition containing nalmefene hydrochloride and preparation method of same | |
| Yokagawa et al. | Brain regional pharmacokinetics of biperiden in rats | |
| CN113337570A (en) | Mechanism analysis system for drug target of depression and drug addiction disease | |
| Wu et al. | A systematic review and meta-analysis of high-frequency prescription of zhigancao decoction combined with conventional western medicine in the treatment of chronic heart failure | |
| Lavoie-Charland et al. | Multivariate asthma phenotypes in adults: the Quebec City case-control asthma cohort | |
| CN103588859A (en) | Centipede active peptide and application thereof in pharmacy | |
| Maeda et al. | Co-treatment with azelinidipine and olmesartan inhibits advanced glycation end products (AGEs) elicited down-regulation of adiponectin mRNA levels in cultured adipocytes partly via its anti-oxidative property | |
| Cui et al. | Safety, tolerability and pharmacokinetics of single dose polyethylene glycolated exenatide injection (PB-119) in healthy volunteers | |
| CN110325851A (en) | A kind of method of evaluating drug effect of reverse multiple drug resistance of tumor drug | |
| Mori et al. | Stereoselective pharmacokinetics and pharmacodynamics of verapamil and norverapamil in rabbits | |
| CN103751766B (en) | Cobra-venom cardiotoxin cardiotoxins is preparing the application in anti-inflammatory and antalgic, arthritis medicine | |
| CN109709241A (en) | The measuring method of high molecular weight substance in Chinese medicine injection containing liposoluble ingredient | |
| CN103272248A (en) | Application of miR-15b in preparing diabetes diagnosis and treatment preparation | |
| CN106771007A (en) | The detection method and test strips of dexamethasone in a kind of dairy products |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210831 |
|
| RJ01 | Rejection of invention patent application after publication |